San Diego, CA
Oct 11 – Oct 13
Join our company presentation with Cenk Sumen, Maxcyte Chief Scientific Officer, at The Cell & Gene Meeting on the Mesa, see details below. The Cell & Gene Meeting is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.
The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,200 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
Featured Event
Thursday, October 12th at 4:45 pm
Location: Oxford Biomedica Ballroom
Join our company presentation with Cenk Sumen, Maxcyte Chief Scientific Officer, to learn about our cell-engineering technologies that help bring next‐generation cell-based therapies to life.
MaxCyte® is a leading provider of cell-engineering platform technologies and is responsible for helping to bring next‐generation cell-based therapies to life. The company’s technology is employed by leading drug developers worldwide, including 20 of the top 25 global biopharmaceutical companies. Our Flow Electroporation® technology and next-generation ExPERTTM platform enable our partners to accelerate, streamline, and improve the drug development process from the early stages of research to commercialization.
Presenter:
Cenk Sumen
Chief Scientific Officerr
Dr. Sumen boasts over a decade of scientific, technological and business development expertise, with extensive time in leadership roles for Stemson Therapeutics, where he was the Chief Technology Officer and led all aspects of technology, scale-up, process development and automation, as well as Thermo Fisher Scientific and Hitachi Chemical Advanced Therapeutics Solutions.
He holds a Ph.D. in Microbiology and Immunology from Stanford University, post-doctoral training at Harvard and a fellowship at the Cancer Research Institute, working at Memorial Sloan Kettering Cancer Center under Nobel Laureate Dr. Jim Allison. He is also currently an Adjunct Professor in the Department of Chemical and Biomolecular Engineering at the NYU Tandon School of Engineering.
